I can’t verify the headline about FDA clearance from the available results. The QurAlis news and pipeline information shown here instead describes QRL-201’s pivotal ALS trial as being planned for 2027; it does not confirm that an FDA IND has been cleared.
QRL-201 is an investigational therapy designed to restore STMN2 expression, a protein whose production can be disrupted in ALS. It is being studied in the Phase 1/2 ANQUR trial.
QurAlis reported interim ANQUR findings in February 2026, including evidence of target engagement and a biomarker signal. The company said it was preparing a pivotal trial, while describing initiation as expected in 2027.
An IND clearance would allow a company to proceed with a proposed US clinical study, but it is not FDA approval of the drug or proof of effectiveness. The exact announcement and its date should be confirmed against QurAlis’s original release.
Sources:
QurAlis Demonstrates Effects on Disease Progression and Target Engagement in ...
QurAlis Reports ANQUR Interim Data for STATHMIN-2- ...
Driving scientific breakthroughs into powerful precision ...
Driving scientific breakthroughs into powerful precision ...
Presentations and Publications
QurAlis Receives Health Canada Clinical Trial Application ...